- |||||||||| buprenorphine depot (ALA-1000) / Alar Pharma
Journal: Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study. (Pubmed Central) - Oct 19, 2024
Interestingly, strong hydrophobic interactions were also observed with the C-terminal tail residues, such as PHE997 and ALA1000 as well as with ARG999 for the YSIPKSS peptide and most of the conjugates...Overall, our results show that the (7-DGA)2-K, di-conjugate, the (7-DGA)2-Y di-conjugate, and the neat YSIPKSS demonstrated strong and stable binding with the L858R mutant and the highly resistant triple mutant EGFR, respectively. The novel designed conjugates demonstrate potential for further optimization for laboratory studies aimed at developing new therapeutics for targeting specific EGFR mutant expressing cells.
- |||||||||| buprenorphine depot (ALA-1000) / Alar Pharma
Trial completion, Trial completion date, Trial primary completion date: Single Ascending Dose Study of ALA-1000 (clinicaltrials.gov) - Dec 30, 2021
P1, N=59, Completed,
The novel designed conjugates demonstrate potential for further optimization for laboratory studies aimed at developing new therapeutics for targeting specific EGFR mutant expressing cells. Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> May 2021 | Trial primary completion date: Aug 2021 --> May 2021
- |||||||||| buprenorphine depot (ALA-1000) / Alar Pharma
Enrollment closed, Trial completion date, Trial primary completion date: Single Ascending Dose Study of ALA-1000 (clinicaltrials.gov) - Apr 29, 2021
P1, N=59, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> May 2021 | Trial primary completion date: Aug 2021 --> May 2021 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Sep 2020 --> Aug 2021
|
